Jennifer Quigley

Company: BioNTech RNA Pharmaceuticals

Job title: Senior Director & Head Precision Health & Partnerships

Bio:

Jennifer leads US Precision Health & Partnerships at BioNTech and is an advisor to BioNTech’s global precision health strategy with a focus on precision medicine strategy, integration, and implementation of biomarker testing for clinical decisions and manufacturing that is consistent and seamless pre-through post launch. Outside of work, Jen is active in improving patient access to precision medicine through innovation and design; she is an Expert in Residence for DigitalDx, a venture capital firm investing-advising novel diagnostic and data companies, treasurer and founding member of the International Society of Health Design Thinking (INSIGHT), and an active member of the Personalized Medicine Coalition (PMC).

Prior to BioNTech, Jennifer was Senior Director of Global Precision Diagnostics at Novartis, where she had responsibility for renal diseases and malignant and non-malignant hematology programs. Before joining pharma, Jen spent two decades in US specialty labs where she held leadership positions in strategy, marketing, sales, and research. She led and oversaw the building of LabCorp Oncology’s new product commercialization program and end-to-end services across biopharma, partner, and internally driven diagnostic portfolio management and launches. Prior to LabCorp, Jen held leadership positions at PathAI, Miraca Life Sciences / Caris Life Sciences, and Integrated Oncology / DIANON Systems. She has launched over twenty diagnostic tests and programs.
Jennifer studied at the University of Pittsburgh and Carnegie Mellon University. She cherishes her time with her husband, Michael, their children, and extended family and friends.

Seminars:

Partnering for success: What Biopharma Needs for Digital Pathology Vendors to be Considered as a Commercialization Partner 4:30 pm

What criteria is most important? How can vendors demonstrate commercial readiness across criteria? Ensuring global readiness and our collective effortsRead more

day: Conference Day One

Panel Discussion: Closing the Gaps in Regulatory Guidance to Improve Biopharma Adherence to Ambiguous Guidelines 2:15 pm

Navigating pre-submission & cohort design: meeting fda expectations for AI tools Where do current regulatory frameworks fall short in addressing AI and digital pathology integration? What pre-submission strategies are most effective when engaging regulators on AI-based pathology tools? What guidance is needed to support the clinical use of exploratory tools for biomarker and CDx development?…Read more

day: Conference Day Two